Compare TAYD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAYD | MOLN |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 157.8M |
| IPO Year | N/A | 2021 |
| Metric | TAYD | MOLN |
|---|---|---|
| Price | $58.88 | $4.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 6.1K | 3.5K |
| Earning Date | 01-05-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $44,593,219.00 | N/A |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $8.37 | $1,000.00 |
| P/E Ratio | $20.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.50 | $3.36 |
| 52 Week High | $59.74 | $5.91 |
| Indicator | TAYD | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 74.05 | 55.40 |
| Support Level | $55.32 | $3.98 |
| Resistance Level | $52.00 | $4.40 |
| Average True Range (ATR) | 2.34 | 0.18 |
| MACD | 0.93 | -0.01 |
| Stochastic Oscillator | 92.96 | 68.12 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.